An Update of Gonadotropin-Releasing Hormone Antagonists in the Treatment of Advanced Prostate Cancer
Korean Journal of Urological Oncology
; : 79-91, 2021.
Article
em Ko
| WPRIM
| ID: wpr-902539
Biblioteca responsável:
WPRO
ABSTRACT
For decades, androgen deprivation therapy (ADT) was the cornerstone treatment for advanced prostate cancer. ADT using gonadotropin-releasing hormone (GnRH) agonist or antagonist acts by blocking the hypothalamic-pituitary-gonadal system with different mechanism. Both injectable GnRH agonist and antagonist are currently used as a standard of care. The novel oral GnRH antagonist has recently approved and it may have a promising alternative to the conventional ADT. This review will focus on the history of drug development, efficacy and safety profiles for GnRH antagonists in patients with prostate cancer.
Texto completo:
1
Índice:
WPRIM
Idioma:
Ko
Revista:
Korean Journal of Urological Oncology
Ano de publicação:
2021
Tipo de documento:
Article